INDUSTRY OVERVIEW
The HER2 Targeted Therapy is Growing at 13% and is expected to reach 70Billion by 2031. Below mentioned are some of the dynamics shaping the HER2 Targeted Therapy .HER2 Targeted Therapy Market Size in (USD Billion) CAGR Growth Rate 13%
| Study Period | 2019-2031 |
| Market Size (2023): | 30Billion |
| Market Size (2031): | 70Billion |
| CAGR (2023 - 2031): | 13% |
| Fastest Growing Region | Asia Pacific |
| Domination Region | North America |
www.www.htfmarketinsights.com
HER2 treatments are a class of drugs that are used to treat HER2-positive breast cancer at all stages, from early-stage to metastatic. Breast cancer that has spread to other regions of the body, such as the bones or liver, is known as metastatic breast cancer. The HER2 gene malfunctions in HER2-positive breast cancer and produces too many copies of itself. These additional HER2 genes result in an excess of HER2 receptor proteins. The HER2 receptors on the surface of breast cells are similar to ears or antennae. Signals are received by the HER2 receptors, which drive the cell to grow and reproduce.
Need More Details on Market Players and Competitors?
DOWNLOAD Sample Report
Market Drivers:
The key drivers in the market include technological advancements, increasing demand by consumers for innovative products, and government-friendly policies. Our research company combines industry reports with expert interviews and market analysis tools to identify and quantify drivers such as these. We review the current trends and gather data from leading industry publications and market research firms to decipher exactly how these and other factors are encouraging or dampening market growth.
- Breast Cancer Cases Are Increasing Is And There Is A Great Demand For Effective Therapeutics
Market Restraints:
Some of the restraints to market growth may include regulatory challenges, high production costs, and disruptions in the supply chain. Our sources for these limitations include the regulation filings, industry surveys, and direct contributions from active participants within this marketplace. Tracking policy updates and economic reports further helps us to determine what kind of effect these factors have on the industry.
- Regulatory Approval
Trends in the Market:
Among the trending ones are sustainability, digital transformation, and increasing importance of data analytics. Our research company is tracking these trends through the use of trend analysis tools, social media sentiment analysis, and industry benchmarking studies. Insights in emerging market preferences and technological advancements also come from surveys and focus groups.
- Healthcare
These include emerging markets, innovation in product development, and strategic partnerships. We identify these opportunities by performing market segmentation analysis, competitive landscape assessment, and investment trend evaluation. The data is collected based on industry reports, financial performance analysis for major players, and forecasting models for identifying future growth areas.
- The Patient Population With Brain Metastases Is The Most Untapped Market
Check Out Prices
Get Price
Regulation Shaping the Healthcare Industry
The healthcare industry is significantly influenced by a complex framework of regulations designed to ensure patient safety, efficacy of treatments, and the overall quality of care. Key regulatory areas include drug approval processes, medical device standards, and healthcare data protection. These regulations aim to maintain high standards for clinical practices and safeguard public health.Major Regulatory Bodies Worldwide
1. U.S. Food and Drug Administration (FDA): In the United States, the FDA is a pivotal regulatory authority overseeing the approval and monitoring of pharmaceuticals, medical devices, and biologics. The FDA sets stringent standards for product safety and efficacy, which significantly impacts market entry and ongoing compliance for healthcare companies.2. European Medicines Agency (EMA): The EMA plays a crucial role in the European Union, evaluating and supervising medicinal products. It provides centralized approval for drugs and ensures that products meet rigorous safety and efficacy standards across member states.
3. Health Canada: This agency regulates pharmaceuticals and medical devices in Canada, ensuring that products are safe, effective, and of high quality. Health Canada's regulations are aligned with international standards but tailored to meet national health needs.
4. World Health Organization (WHO): While not a regulatory body in the traditional sense, the WHO sets international health standards and provides guidelines that influence national regulatory frameworks. It plays a key role in global health policy and emergency response.
5. National Medical Products Administration (NMPA): In China, the NMPA regulates the approval and supervision of drugs and medical devices, with an increasing focus on aligning with global standards and facilitating market access.
Request for Customization
Get Customization
SWOT Analysis in the Healthcare Industry
SWOT analysis in the healthcare industry involves a structured assessment of Strengths, Weaknesses, Opportunities, and Threats to identify strategic advantages and areas for improvement.• Strengths: Evaluates internal factors such as advanced technology, skilled personnel, and strong brand reputation. For example, a hospital with cutting-edge medical equipment and specialized staff is considered to have a strong competitive edge.
• Weaknesses: Identifies internal limitations like outdated facilities, regulatory compliance issues, or high operational costs. Weaknesses could include inefficient processes or lack of innovation.
• Opportunities: Assesses external factors that could drive growth, such as emerging medical technologies, expanding markets, or favorable government policies. Opportunities might involve partnerships or new service lines.
• Threats: Examines external challenges such as increasing competition, changing regulations, or economic downturns. Threats might include new entrants with disruptive technologies or stricter regulatory requirements.
Market Segmentation
Segmentation by Type
- Monoclonal Antibodies
- Small Molecules
- Combination Therapy
- Immunotherapy
HER2 Targeted Therapy Market Segmentation by Type
www.htfmarketinsights.com
Segmentation by Application
- Oncology
- Pharmaceuticals
- Research
- Hospitals
- Clinics
HER2 Targeted Therapy Market Segmentation by Application
www.htfmarketinsights.com
Regional Outlook
The North America currently holds a significant share of the market, primarily due to several key factors: increasing consumption rates, a burgeoning population, and robust economic momentum. These elements collectively drive demand, positioning this region as a leader in the market. On the other hand, Asia Pacific is rapidly emerging as the fastest-growing area within the industry. This remarkable growth can be attributed to swift infrastructure development, the expansion of various industrial sectors, and a marked increase in consumer demand. These dynamics make this region a crucial player in shaping future market growth. In our report, we cover a comprehensive analysis of the regions and countries, includingRegions
- North America
- LATAM
- West Europe
- Central & Eastern Europe
- Northern Europe
- Southern Europe
- East Asia
- Southeast Asia
- South Asia
- Central Asia
- Oceania
- MEA
Fastest Growing Region
Asia Pacific
Dominating Region
North America
The company consistently allocates significant resources to expand its research capabilities, develop new medical technologies, and enhance its pharmaceutical portfolio. Johnson & Johnson's investments in R&D, coupled with strategic acquisitions and partnerships, reinforce its position as a major contributor to advancements in healthcare. This focus on innovation and market expansion underscores the critical importance of the North American region in the global healthcare landscape.
- Roche (Switzerland)
- Sanofi (France)
- Byondis (Netherlands)
- Novartis (Switzerland)
- Astrazeneca (United Kingdom)
- Daiichi Sankyo (Japan)
- Genentech (United States)
- Bristol Myers Squibb (United States)
- Eisai (Japan)
- Kyowa Kirin (Japan)
HER2 Targeted Therapy Market Segmentation by Players
www.htfmarketinsights.com
Primary and Secondary Research
Primary research involves the collection of original data directly from sources in the healthcare industry. Approaches include the survey of health professionals, interviews with patients, focus groups, and clinical trials. This gives an overview of the current practice, the needs of the patient, and the interest in emerging trends. Firsthand information on the efficacy of new treatments, an assessment of market demand, and insight into changes in regulation can be sought only with primary research.Secondary Research: This is the investigation of existing information from a variety of sources, which may include industry reports, academic journals, government publications, and market research studies. Alfred secondary research empowers them to understand trends within industries, historical data, and competitive landscapes. It gives a wide view of the market dynamics and validates findings obtained from primary research. By combining both primary and secondary together, health organizations will be empowered to develop comprehensive strategies and make informed decisions based on a strong foundation built on data.
Report Infographics
|
Report Features |
Details |
|
Base Year |
2023 |
|
Based Year Market Size (2023) |
30Billion |
|
Historical Period |
2019 to 2023 |
|
CAGR (2023 to 2031) |
13% |
|
Forecast Period |
2023 to 2031 |
|
Forecasted Period Market Size (2031) |
70Billion |
|
Scope of the Report |
Monoclonal Antibodies, Small Molecules, Combination Therapy, Immunotherapy, Oncology, Pharmaceuticals, Research, Hospitals, Clinics. Sales Channel |
|
Regions Covered |
North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA |
|
Companies Covered |
Roche (Switzerland), Sanofi (France), Byondis (Netherlands), Novartis (Switzerland), Astrazeneca (United Kingdom), Daiichi Sankyo (Japan), Genentech (United States), Bristol Myers Squibb (United States), Eisai (Japan), Kyowa Kirin (Japan) |
|
Customization Scope |
15% Free Customization (For EG) |
|
Delivery Format |
PDF and Excel through Email |
HER2 Targeted Therapy - Table of Contents
Chapter 1: Market Preface
- 1.1 Global HER2 Targeted Therapy Market Landscape
- 1.2 Scope of the Study
- 1.3 Relevant Findings & Stakeholder Advantages
Chapter 2: Strategic Overview
- 2.1 Global HER2 Targeted Therapy Market Outlook
- 2.2 Total Addressable Market versus Serviceable Market
- 2.3 Market Rivalry Projection
Chapter 3 : Global HER2 Targeted Therapy Market Business Environment & Changing Dynamics
-
3.1 Growth Drivers
- 3.1.1 Breast Cancer Cases are Increasing is and there is a Great Demand for Effective Therapeutics
-
3.2 Available Opportunities
- 3.2.1 The Patient Population with Brain Metastases is the Most Untapped Market
-
3.3 Influencing Trends
- 3.3.1 Healthcare
- 3.3.2 cancer treatment
-
3.4 Challenges
- 3.4.1 Regulatory approval
- 3.4.2 market competition
- 3.5 Regional Dynamics
Need only Qualitative Analysis? Get Prices
Sectional Purchase
Chapter 4 : Global HER2 Targeted Therapy Industry Factors Assessment
- 4.1 Current Scenario
- 4.2 PEST Analysis
- 4.3 Business Environment - PORTER 5-Forces Analysis
- 4.3.1 Supplier Leverage
- 4.3.2 Bargaining Power of Buyers
- 4.3.3 Threat of Substitutes
- 4.3.4 Threat from New Entrant
- 4.3.5 Market Competition Level
- 4.4 Roadmap of HER2 Targeted Therapy Market
- 4.5 Impact of Macro-Economic Factors
- 4.6 Market Entry Strategies
- 4.7 Political and Regulatory Landscape
- 4.8 Supply Chain Analysis
Chapter 5: HER2 Targeted Therapy : Competition Benchmarking & Performance Evaluation
- 5.1 Global HER2 Targeted Therapy Market Concentration Ratio
- 5.1.1 CR4, CR8 and HH Index
- 5.1.2 % Market Share - Top 3
- 5.1.3 Market Holding by Top 5
- 5.2 Market Position of Manufacturers by HER2 Targeted Therapy Revenue 2023
- 5.3 Global HER2 Targeted Therapy Sales Volume by Manufacturers (2023)
- 5.4 BCG Matrix
- 5.4 Market Entropy
- 5.5 Heat Map Analysis
- 5.6 Strategic Group Analysis
Chapter 6: Global HER2 Targeted Therapy Market: Company Profiles
- 6.1 Roche (Switzerland)
- 6.1.1 Roche (Switzerland) Company Overview
- 6.1.2 Roche (Switzerland) Product/Service Portfolio & Specifications
- 6.1.3 Roche (Switzerland) Key Financial Metrics
- 6.1.4 Roche (Switzerland) SWOT Analysis
- 6.1.5 Roche (Switzerland) Development Activities
- 6.2 Sanofi (France)
- 6.3 Byondis (Netherlands)
- 6.4 Novartis (Switzerland)
- 6.5 Astrazeneca (United Kingdom)
- 6.6 Daiichi Sankyo (Japan)
- 6.7 Genentech (United States)
- 6.8 Bristol Myers Squibb (United States)
- 6.9 Eisai (Japan)
- 6.10 Kyowa Kirin (Japan)
- 6.11
To View a Complete List of Players? Inquiry Now
Sectional Purchase
Chapter 7 : Global HER2 Targeted Therapy by Type & Application (2019-2031)
-
7.1 Global HER2 Targeted Therapy Market Revenue Analysis (USD Million) by Type (2019-2023)
- 7.1.1 Monoclonal Antibodies
- 7.1.2 Small Molecules
- 7.1.3 Combination Therapy
- 7.1.4 Immunotherapy
- 7.1.5 Gene Therapy
-
7.2 Global HER2 Targeted Therapy Market Revenue Analysis (USD Million) by Application (2019-2023)
- 7.2.1 Oncology
- 7.2.2 Pharmaceuticals
- 7.2.3 Research
- 7.2.4 Hospitals
- 7.2.5 Clinics
- 7.3 Global HER2 Targeted Therapy Market Revenue Analysis (USD Million) by Type (2023-2031)
- 7.4 Global HER2 Targeted Therapy Market Revenue Analysis (USD Million) by Application (2023-2031)
Chapter 8 : North America HER2 Targeted Therapy Market Breakdown by Country, Type & Application
- 8.1 North America HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 8.1.1 United States
- 8.1.2 Canada
-
8.2 North America HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 8.2.1 Monoclonal Antibodies
- 8.2.2 Small Molecules
- 8.2.3 Combination Therapy
- 8.2.4 Immunotherapy
- 8.2.5 Gene Therapy
-
8.3 North America HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 8.3.1 Oncology
- 8.3.2 Pharmaceuticals
- 8.3.3 Research
- 8.3.4 Hospitals
- 8.3.5 Clinics
- 8.4 North America HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 8.5 North America HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 8.6 North America HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Looking for Section Purchase? Get Quote Now
Sectional Purchase
Chapter 9 : LATAM HER2 Targeted Therapy Market Breakdown by Country, Type & Application
- 9.1 LATAM HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 9.1.1 Brazil
- 9.1.2 Argentina
- 9.1.3 Chile
- 9.1.4 Mexico
- 9.1.5 Rest of LATAM
-
9.2 LATAM HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 9.2.1 Monoclonal Antibodies
- 9.2.2 Small Molecules
- 9.2.3 Combination Therapy
- 9.2.4 Immunotherapy
- 9.2.5 Gene Therapy
-
9.3 LATAM HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 9.3.1 Oncology
- 9.3.2 Pharmaceuticals
- 9.3.3 Research
- 9.3.4 Hospitals
- 9.3.5 Clinics
- 9.4 LATAM HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 9.5 LATAM HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 9.6 LATAM HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 10 : West Europe HER2 Targeted Therapy Market Breakdown by Country, Type & Application
- 10.1 West Europe HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 10.1.1 Germany
- 10.1.2 France
- 10.1.3 Benelux
- 10.1.4 Switzerland
- 10.1.5 Rest of West Europe
-
10.2 West Europe HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 10.2.1 Monoclonal Antibodies
- 10.2.2 Small Molecules
- 10.2.3 Combination Therapy
- 10.2.4 Immunotherapy
- 10.2.5 Gene Therapy
-
10.3 West Europe HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 10.3.1 Oncology
- 10.3.2 Pharmaceuticals
- 10.3.3 Research
- 10.3.4 Hospitals
- 10.3.5 Clinics
- 10.4 West Europe HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 10.5 West Europe HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 10.6 West Europe HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 11 : Central & Eastern Europe HER2 Targeted Therapy Market Breakdown by Country, Type & Application
- 11.1 Central & Eastern Europe HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 11.1.1 Bulgaria
- 11.1.2 Poland
- 11.1.3 Hungary
- 11.1.4 Romania
- 11.1.5 Rest of CEE
-
11.2 Central & Eastern Europe HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 11.2.1 Monoclonal Antibodies
- 11.2.2 Small Molecules
- 11.2.3 Combination Therapy
- 11.2.4 Immunotherapy
- 11.2.5 Gene Therapy
-
11.3 Central & Eastern Europe HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 11.3.1 Oncology
- 11.3.2 Pharmaceuticals
- 11.3.3 Research
- 11.3.4 Hospitals
- 11.3.5 Clinics
- 11.4 Central & Eastern Europe HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 11.5 Central & Eastern Europe HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 11.6 Central & Eastern Europe HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 12 : Northern Europe HER2 Targeted Therapy Market Breakdown by Country, Type & Application
- 12.1 Northern Europe HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 12.1.1 The United Kingdom
- 12.1.2 Sweden
- 12.1.3 Norway
- 12.1.4 Baltics
- 12.1.5 Ireland
- 12.1.6 Rest of Northern Europe
-
12.2 Northern Europe HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 12.2.1 Monoclonal Antibodies
- 12.2.2 Small Molecules
- 12.2.3 Combination Therapy
- 12.2.4 Immunotherapy
- 12.2.5 Gene Therapy
-
12.3 Northern Europe HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 12.3.1 Oncology
- 12.3.2 Pharmaceuticals
- 12.3.3 Research
- 12.3.4 Hospitals
- 12.3.5 Clinics
- 12.4 Northern Europe HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 12.5 Northern Europe HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 12.6 Northern Europe HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 13 : Southern Europe HER2 Targeted Therapy Market Breakdown by Country, Type & Application
- 13.1 Southern Europe HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 13.1.1 Spain
- 13.1.2 Italy
- 13.1.3 Portugal
- 13.1.4 Greece
- 13.1.5 Rest of Southern Europe
-
13.2 Southern Europe HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 13.2.1 Monoclonal Antibodies
- 13.2.2 Small Molecules
- 13.2.3 Combination Therapy
- 13.2.4 Immunotherapy
- 13.2.5 Gene Therapy
-
13.3 Southern Europe HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 13.3.1 Oncology
- 13.3.2 Pharmaceuticals
- 13.3.3 Research
- 13.3.4 Hospitals
- 13.3.5 Clinics
- 13.4 Southern Europe HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 13.5 Southern Europe HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 13.6 Southern Europe HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 14 : East Asia HER2 Targeted Therapy Market Breakdown by Country, Type & Application
- 14.1 East Asia HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 14.1.1 China
- 14.1.2 Japan
- 14.1.3 South Korea
- 14.1.4 Taiwan
- 14.1.5 Others
-
14.2 East Asia HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 14.2.1 Monoclonal Antibodies
- 14.2.2 Small Molecules
- 14.2.3 Combination Therapy
- 14.2.4 Immunotherapy
- 14.2.5 Gene Therapy
-
14.3 East Asia HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 14.3.1 Oncology
- 14.3.2 Pharmaceuticals
- 14.3.3 Research
- 14.3.4 Hospitals
- 14.3.5 Clinics
- 14.4 East Asia HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 14.5 East Asia HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 14.6 East Asia HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 15 : Southeast Asia HER2 Targeted Therapy Market Breakdown by Country, Type & Application
- 15.1 Southeast Asia HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 15.1.1 Vietnam
- 15.1.2 Singapore
- 15.1.3 Thailand
- 15.1.4 Malaysia
- 15.1.5 Indonesia
- 15.1.6 Philippines
- 15.1.7 Rest of SEA Countries
-
15.2 Southeast Asia HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 15.2.1 Monoclonal Antibodies
- 15.2.2 Small Molecules
- 15.2.3 Combination Therapy
- 15.2.4 Immunotherapy
- 15.2.5 Gene Therapy
-
15.3 Southeast Asia HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 15.3.1 Oncology
- 15.3.2 Pharmaceuticals
- 15.3.3 Research
- 15.3.4 Hospitals
- 15.3.5 Clinics
- 15.4 Southeast Asia HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 15.5 Southeast Asia HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 15.6 Southeast Asia HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 16 : South Asia HER2 Targeted Therapy Market Breakdown by Country, Type & Application
- 16.1 South Asia HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 16.1.1 India
- 16.1.2 Bangladesh
- 16.1.3 Others
-
16.2 South Asia HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 16.2.1 Monoclonal Antibodies
- 16.2.2 Small Molecules
- 16.2.3 Combination Therapy
- 16.2.4 Immunotherapy
- 16.2.5 Gene Therapy
-
16.3 South Asia HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 16.3.1 Oncology
- 16.3.2 Pharmaceuticals
- 16.3.3 Research
- 16.3.4 Hospitals
- 16.3.5 Clinics
- 16.4 South Asia HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 16.5 South Asia HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 16.6 South Asia HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 17 : Central Asia HER2 Targeted Therapy Market Breakdown by Country, Type & Application
- 17.1 Central Asia HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 17.1.1 Kazakhstan
- 17.1.2 Tajikistan
- 17.1.3 Others
-
17.2 Central Asia HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 17.2.1 Monoclonal Antibodies
- 17.2.2 Small Molecules
- 17.2.3 Combination Therapy
- 17.2.4 Immunotherapy
- 17.2.5 Gene Therapy
-
17.3 Central Asia HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 17.3.1 Oncology
- 17.3.2 Pharmaceuticals
- 17.3.3 Research
- 17.3.4 Hospitals
- 17.3.5 Clinics
- 17.4 Central Asia HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 17.5 Central Asia HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 17.6 Central Asia HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 18 : Oceania HER2 Targeted Therapy Market Breakdown by Country, Type & Application
- 18.1 Oceania HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 18.1.1 Australia
- 18.1.2 New Zealand
- 18.1.3 Others
-
18.2 Oceania HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 18.2.1 Monoclonal Antibodies
- 18.2.2 Small Molecules
- 18.2.3 Combination Therapy
- 18.2.4 Immunotherapy
- 18.2.5 Gene Therapy
-
18.3 Oceania HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 18.3.1 Oncology
- 18.3.2 Pharmaceuticals
- 18.3.3 Research
- 18.3.4 Hospitals
- 18.3.5 Clinics
- 18.4 Oceania HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 18.5 Oceania HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 18.6 Oceania HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 19 : MEA HER2 Targeted Therapy Market Breakdown by Country, Type & Application
- 19.1 MEA HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 19.1.1 Turkey
- 19.1.2 South Africa
- 19.1.3 Egypt
- 19.1.4 UAE
- 19.1.5 Saudi Arabia
- 19.1.6 Israel
- 19.1.7 Rest of MEA
-
19.2 MEA HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 19.2.1 Monoclonal Antibodies
- 19.2.2 Small Molecules
- 19.2.3 Combination Therapy
- 19.2.4 Immunotherapy
- 19.2.5 Gene Therapy
-
19.3 MEA HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 19.3.1 Oncology
- 19.3.2 Pharmaceuticals
- 19.3.3 Research
- 19.3.4 Hospitals
- 19.3.5 Clinics
- 19.4 MEA HER2 Targeted Therapy Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 19.5 MEA HER2 Targeted Therapy Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 19.6 MEA HER2 Targeted Therapy Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 20: Research Findings & Conclusion
- 20.1 Key Findings
- 20.2 Conclusion
Chapter 21: Methodology and Data Source
-
21.1 Research Methodology & Approach
- 21.1.1 Research Program/Design
- 21.1.2 Market Size Estimation
- 21.1.3 Market Breakdown and Data Triangulation
-
21.2 Data Source
- 21.2.1 Secondary Sources
- 21.2.2 Primary Sources
Chapter 22: Appendix & Disclaimer
- 22.1 Acronyms & bibliography
- 22.2 Disclaimer
Frequently Asked Questions (FAQ):
The HER2 Targeted Therapy market is estimated to derive a market size of 70Billion by 2031.
The HER2 Targeted Therapy Market is estimated to grow at a CAGR of 13%, currently pegged at 30Billion.
The changing dynamics and trends such as Healthcare, Cancer Treatment are seen as major Game Changer in Global HER2 Targeted Therapy Market.
The leaders in the Global HER2 Targeted Therapy Market such as Roche (Switzerland), Sanofi (France), Byondis (Netherlands), Novartis (Switzerland), Astrazeneca (United Kingdom), Daiichi Sankyo (Japan), Genentech (United States), Bristol Myers Squibb (United States), Eisai (Japan), Kyowa Kirin (Japan), are targeting innovative and differentiated growth drivers some of them are Breast Cancer Cases Are Increasing Is And There Is A Great Demand For Effective Therapeutics
Some of the major roadblocks that industry players have identified are Regulatory Approval, Market Competition.
Some of the opportunities that Analyst at HTF MI have identified in HER2 Targeted Therapy Market are:
- The Patient Population With Brain Metastases Is The Most Untapped Market
HER2 Targeted Therapy Market identifies market share by players along with the concentration rate using CR4, CR8 Index to determine leading and emerging competitive players such as Roche (Switzerland), Sanofi (France), Byondis (Netherlands), Novartis (Switzerland), Astrazeneca (United Kingdom), Daiichi Sankyo (Japan), Genentech (United States), Bristol Myers Squibb (United States), Eisai (Japan), Kyowa Kirin (Japan), .
Research paper of Global HER2 Targeted Therapy Market shows that companies are making better progress than their supply chain peers –including suppliers, majorly in end-use applications such as Oncology, Pharmaceuticals, Research, Hospitals, Clinics.
The Global HER2 Targeted Therapy Market Study is segmented by Monoclonal Antibodies, Small Molecules, Combination Therapy, Immunotherapy, Gene Therapy.
The Global HER2 Targeted Therapy Market Study includes regional breakdown as North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA
Historical Year: 2019 - Base year: 2023. Forecast period**: 2025 to 2031 [** unless otherwise stated]
HER2 treatments are a class of drugs that are used to treat HER2-positive breast cancer at all stages, from early-stage to metastatic. Breast cancer that has spread to other regions of the body, such as the bones or liver, is known as metastatic breast cancer. The HER2 gene malfunctions in HER2-positive breast cancer and produces too many copies of itself. These additional HER2 genes result in an excess of HER2 receptor proteins. The HER2 receptors on the surface of breast cells are similar to ears or antennae. Signals are received by the HER2 receptors, which drive the cell to grow and reproduce.
